News | February 18, 2022
Bayer raises peak sales for Nubeqa to exceed €3 billion
Darolutamide is developed jointly by Bayer and Orion Corporation
Darolutamide is developed jointly by Bayer and Orion Corporation
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Resolv ER may remedy leading causes of blindness in adults
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Subscribe To Our Newsletter & Stay Updated
